OBJECTIVE: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to enhance new bone formation in fracture and bone defect models in both normal and diabetic rats. Effects of rhBMP-2 in a segmental femoral defect model in diabetes mellitus (DM) BB Wistar rats have not been reported. METHODS: Collagen sponge soaked with either buffer or rhBMP-2 was inserted in a mid-diaphyseal 3.0-mm defect fixed with polyimide plate and stainless steel screws, in 62 DM BB Wistar rats. Progress of new bone formation in the defect was monitored with serial radiographs every 2 weeks. Histomorphometric analysis of the new bone formation was done on undecalcified sections of the extracted femurs at 3 and 6 weeks post surgery. Further analysis of the new bone was done by assessment of neoangiogenesis using immunohistochemical staining for Platelet endothelial cell adhesion molecule-1. Mechanical testing was performed at 9 weeks to assess the new bone with respect to 4 different parameters of mechanical and structural properties of bone. RESULTS: Radiographs assessed over a 6-point grading system showed statistically significant improvement in scores in rhBMP-2-treated rats at 6 weeks (P < 0.001). Histomorphometric analysis showed statistically significant increase in area of new bone formation between rats treated with rhBMP-2 compared with buffer at both 3 and 6 weeks (P < 0.001). On Platelet endothelial cell adhesion molecule-1 staining at 3 weeks, the mean number of vessels in rhBMP-2-treated DM rats was 12.76 +/- 5.43/mm(2) compared with 4.49 +/- 1.89/mm(2) in buffer treated DM rats (P = 0.034). On mechanical testing, all 4 DM/buffer rats had nonunion. In DM/rhBMP-2 rats, the torque to failure and torsional rigidity values were 393.57 +/- 233.3 (P < 0.03) and 29,711 +/- 6224 (P < 0.002), respectively. CONCLUSIONS: Clearly, although DM has a known impact on osseous healing, its negative effects are ameliorated with the application of the rhBMP-2-collagen carrier and demonstrates the potential clinical role of this adjunct in the clinical arena.
OBJECTIVE: Recombinant humanbone morphogenetic protein-2 (rhBMP-2) has been shown to enhance new bone formation in fracture and bone defect models in both normal and diabeticrats. Effects of rhBMP-2 in a segmental femoral defect model in diabetes mellitus (DM) BB Wistar rats have not been reported. METHODS: Collagen sponge soaked with either buffer or rhBMP-2 was inserted in a mid-diaphyseal 3.0-mm defect fixed with polyimide plate and stainless steel screws, in 62 DM BB Wistar rats. Progress of new bone formation in the defect was monitored with serial radiographs every 2 weeks. Histomorphometric analysis of the new bone formation was done on undecalcified sections of the extracted femurs at 3 and 6 weeks post surgery. Further analysis of the new bone was done by assessment of neoangiogenesis using immunohistochemical staining for Platelet endothelial cell adhesion molecule-1. Mechanical testing was performed at 9 weeks to assess the new bone with respect to 4 different parameters of mechanical and structural properties of bone. RESULTS: Radiographs assessed over a 6-point grading system showed statistically significant improvement in scores in rhBMP-2-treated rats at 6 weeks (P < 0.001). Histomorphometric analysis showed statistically significant increase in area of new bone formation between rats treated with rhBMP-2 compared with buffer at both 3 and 6 weeks (P < 0.001). On Platelet endothelial cell adhesion molecule-1 staining at 3 weeks, the mean number of vessels in rhBMP-2-treated DMrats was 12.76 +/- 5.43/mm(2) compared with 4.49 +/- 1.89/mm(2) in buffer treated DMrats (P = 0.034). On mechanical testing, all 4 DM/buffer rats had nonunion. In DM/rhBMP-2 rats, the torque to failure and torsional rigidity values were 393.57 +/- 233.3 (P < 0.03) and 29,711 +/- 6224 (P < 0.002), respectively. CONCLUSIONS: Clearly, although DM has a known impact on osseous healing, its negative effects are ameliorated with the application of the rhBMP-2-collagen carrier and demonstrates the potential clinical role of this adjunct in the clinical arena.
Authors: Xiaoning He; Rosemary Dziak; Keya Mao; Robert Genco; Mark Swihart; Mark Swithart; Chunyi Li; Shuying Yang Journal: Tissue Eng Part A Date: 2012-11-16 Impact factor: 3.845
Authors: Abigail M Wojtowicz; Asha Shekaran; Megan E Oest; Kenneth M Dupont; Kellie L Templeman; Dietmar W Hutmacher; Robert E Guldberg; Andrés J García Journal: Biomaterials Date: 2009-12-28 Impact factor: 12.479
Authors: Asha Shekaran; José R García; Amy Y Clark; Taylor E Kavanaugh; Angela S Lin; Robert E Guldberg; Andrés J García Journal: Biomaterials Date: 2014-04-13 Impact factor: 12.479
Authors: Behnoush Khorsand; Nate Nicholson; Anh-Vu Do; John E Femino; James A Martin; Emily Petersen; Brian Guetschow; Douglas C Fredericks; Aliasger K Salem Journal: J Control Release Date: 2017-01-07 Impact factor: 11.467
Authors: Tera M Filion; Jordan D Skelly; Henry Huang; Dale L Greiner; David C Ayers; Jie Song Journal: Stem Cell Res Ther Date: 2017-03-11 Impact factor: 6.832